Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lobaplatin Combined With Etoposide for First-line Treatment in Extensive Stage Sclc Then Benefit Patients Follow up Temozolomide Maintain Therapeutic

NCT02972320 is registered in ClinicalTrials.gov with Yunpeng Liu as lead sponsor.

NCT NCT02972320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02972320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lobaplatin Combined With Etoposide for First-line Treatment in Extensive Stage Sclc Then Benefit Patients Follow up Temozolomide Maintain Therapeutic
Lead sponsor
Yunpeng Liu
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2016
Completion date
December 31, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer